Case Citation
Legal Case Name

Pearson v. Shalala Case Brief

Court of Appeals for the D.C. Circuit1999Docket #64063750
164 F.3d 650 334 U.S. App. D.C. 71 1999 U.S. App. LEXIS 464 1999 WL 12782

Why Top Law Students (And Those Aspiring to Be) Use LSD+ Briefs

Let's be real, law school is a marathon. Our exclusive Flash-to-Full case system is designed by Harvard Law School and MIT grads to match your pace: Quick summaries when you're slammed, detailed analysis when you need to go deep. Only LSD+ offers this kind of flexibility to genuinely fit your study flow.

Adaptive Case Views

Toggle between Flash, Standard, and Expanded. Get what you need, when you need it.

Exam-Ready IRAC Format

We deliver the precise structure professors look for in exam answers.

Complex Cases, Clarified

We break down dense legal reasoning into something digestible, helping you grasp core concepts.

Case Brief Summary & Legal Analysis

General Brief
4 min read

tl;dr: The court reversed the FDA’s denial of dietary supplement health claims, finding the agency violated the First Amendment by not considering disclaimers and the APA by not defining its approval standard.

Legal Significance: This case reinforces that the First Amendment prefers disclaimers over suppression for potentially misleading commercial speech and requires agencies to articulate clear standards for their decisions under the APA.

Pearson v. Shalala Law School Study Guide

Use this case brief structure for your own legal analysis. Focus on the IRAC methodology to excel in law school exams and cold calls.

Case Facts & Court Holding

Key Facts & Case Background

Appellants, marketers of dietary supplements, sought FDA authorization for four health claims on their product labels, such as “Consumption of antioxidant vitamins may reduce the risk of certain kinds of cancers.” The FDA, pursuant to the Nutrition Labeling and Education Act (NLEA) and its regulations (21 C.F.R. § 101.14(c)), authorizes such claims only if it finds “significant scientific agreement” among experts that the claim is supported by available evidence. The FDA rejected all four of appellants’ proposed claims, concluding the evidence was inconclusive and thus did not meet this standard. The agency, however, had not provided a clear definition of “significant scientific agreement.” Furthermore, the FDA refused to consider appellants’ suggestion to authorize the claims if accompanied by disclaimers clarifying the inconclusive nature of the supporting evidence (e.g., “The FDA has determined that the evidence supporting this claim is inconclusive.”). Appellants challenged the FDA’s decisions in district court, arguing violations of their First Amendment rights and the Administrative Procedure Act (APA). The district court rejected their challenges.

Court Holding & Legal Precedent

Issue: Did the FDA’s refusal to authorize appellants’ health claims for dietary supplements, based on an undefined “significant scientific agreement” standard and without considering the use of disclaimers as a less restrictive alternative to a complete ban, violate the First Amendment’s protection of commercial speech and the Administrative Procedure Act?

Yes. The FDA’s refusal to authorize the health claims without adequately considering Lorem ipsum dolor sit amet, consectetur adipiscing elit, sed do eiusmod tempor incididunt ut labore et dolore magna aliqua. Ut enim ad minim veniam, quis nostrud exercitation ullamco laboris nisi ut aliquip ex ea commodo consequat. Duis aute irure dolor in reprehenderit in voluptate velit esse cillum dolore eu fugiat nulla pariatur. Excepteur sint occaecat cupidatat non proident, sunt in culpa qui officia deserunt mollit anim id est laborum. Lorem ipsum dolor sit amet, consectetur adipiscing elit, sed do eiusmod tempor incididunt ut labore et dolore magna aliqua. Ut enim ad minim veniam, quis nostrud exercitation ullamco laboris nisi ut aliquip ex ea commodo consequat. Duis aute irure do

Master Every Case Faster

Unlock premium legal analysis that helps you quickly understand complex cases, designed by Harvard Law and MIT graduates. It's about working smarter, not just harder.

Start 14-Day Free Trial

Thousands of students are already saving time and gaining clarity. Why not you?

IRAC Legal Analysis

Premium Feature Unlock

Complete IRAC Analysis for Higher Grades

IRAC (Issue, Rule, Analysis, Conclusion) is the exact format professors want to see in your exam answers. Our exclusive Flash-to-Full briefs combine holding, analysis, and rule statements formatted to match what A+ students produce in exams. These structured briefs help reinforce the essential legal reasoning patterns expected in law school.

Legal Issue

Did the FDA’s refusal to authorize appellants’ health claims for dietary supplements, based on an undefined “significant scientific agreement” standard and without considering the use of disclaimers as a less restrictive alternative to a complete ban, violate the First Amendment’s protection of commercial speech and the Administrative Procedure Act?

Conclusion

This decision significantly impacts commercial speech doctrine by reinforcing the government's burden Lorem ipsum dolor sit amet, consectetur adipiscing elit, sed do eiusmod tempor incididunt ut labore et dolore magna aliqua. Ut enim ad minim veniam, quis nostrud exercitation ullamco laboris nisi ut aliquip ex ea commodo consequat. Duis aute

Legal Rule

1. Under the First Amendment, restrictions on potentially misleading commercial speech are Lorem ipsum dolor sit amet, consectetur adipiscing elit, sed do eiusmod tempor incididunt ut labore et dolore magna aliqua. Ut enim ad minim veniam, quis nostrud exercitation ullamco laboris nisi ut aliquip ex ea commodo consequat. Duis aute irure dolor in reprehenderit in voluptate velit esse cillum dolore eu fugiat nulla pariatur. Excepteur sint occaecat cupidatat non proident, sunt in culpa qui officia deserunt mollit anim id est laborum. Lorem ipsum dolor sit amet, consectetur adipiscing elit, sed do eiusmod tempor incididunt ut labore et dolore magna aliqua. Ut enim ad minim veniam, quis nostrud exercitation ullamco laboris nisi ut aliquip ex ea commodo consequat. Duis aute irure dolor in reprehenderit in voluptate velit esse cillum dolore eu fugiat nulla pariatur. Excepteur sint occaecat cupidatat non proident, sunt in culpa qui officia deserunt mollit anim id est laborum. Lorem ipsum d

Legal Analysis

The court first analyzed the First Amendment commercial speech claim (Part II.A). Lorem ipsum dolor sit amet, consectetur adipiscing elit, sed do eiusmod tempor incididunt ut labore et dolore magna aliqua. Ut enim ad minim veniam, quis nostrud exercitation ullamco laboris nisi ut aliquip ex ea commodo consequat. Duis aute irure dolor in reprehenderit in voluptate velit esse cillum dolore eu fugiat nulla pariatur. Excepteur sint occaecat cupidatat non proident, sunt in culpa qui officia deserunt mollit anim id est laborum. Lorem ipsum dolor sit amet, consectetur adipiscing elit, sed do eiusmod tempor incididunt ut labore et dolore magna aliqua. Ut enim ad minim veniam, quis nostrud exercitation ullamco laboris nisi ut aliquip ex ea commodo consequat. Duis aute irure dolor in reprehenderit in voluptate velit esse cillum dolore eu fugiat nulla pariatur. Excepteur sint occaecat cupidatat non proident, sunt in culpa qui officia deserunt mollit anim id est laborum. Lorem ipsum dolor sit amet, consectetur adipiscing elit, sed do eiusmod tempor incididunt ut labore et dolore magna aliqua. Ut enim ad minim veniam, quis nostrud exercitation ullamco laboris nisi ut aliquip ex ea commodo consequat. Duis aute irure dolor in reprehenderit in voluptate velit esse cillum dolore eu fugiat nulla pariatur. Excepteur sint occaecat cupidatat non proident, sunt in culpa qui officia deserunt mollit anim id est laborum. Lorem ipsum dolor sit amet, consectetur adipiscing elit, sed do eiusmod tempor incididunt ut labore et dolore magna aliqua. Ut enim ad minim veniam, quis nostrud exercitation ullamco laboris nisi ut aliquip ex ea commodo consequat. Duis aute irure dolor in reprehenderit in voluptate velit esse cillum dolore eu fugiat nulla pariatur. Excepteur sint occaecat cupidatat non proident, sunt in culpa qui officia deserunt mollit anim id es

Flash-to-Full Case Opinions

Flash Summary

  • The FDA’s total ban on dietary supplement health claims not meeting
Lorem ipsum dolor sit amet, consectetur adipiscing elit, sed do eiusmod tempor incididunt ut labore et dolore magna aliqua. Ut enim ad minim veniam, quis nostrud exercitation ullamco laboris nisi ut aliquip ex ea commodo consequat. Duis aute irure dolor in reprehenderit in voluptate velit esse cillum dolore eu fugiat nulla pariatur. Excepteur sint occa

Master Every Case Faster

Unlock premium legal analysis that helps you quickly understand complex cases, designed by Harvard Law and MIT graduates. It's about working smarter, not just harder.

Start 14-Day Free Trial

Thousands of students are already saving time and gaining clarity. Why not you?